Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Recs

2
Player Avatar zzlangerhans (99.82) Submitted: 9/12/2011 10:45:56 PM : Outperform Start Price: $6.49 CRTX Score: -20.97

My old college dorm was voted "Most apathetic" in a student survey, so we all got T-shirts that said "Everyone says we're apathetic, but we don't care." That's pretty much how I feel about Cornerstone. I care just enough to drop a green thumb and a pitch.

Cornerstone is a good candidate for a rebound if broad market parameters improve. Revenues have been stable and the bottom line will benefit from sales of Spectracef and Factive. Impending approval of generic Tussionex may provide another boost. CAPS only, 5-10 points and out.

Report this Post 2 Replies
Member Avatar reachmygoals1 (< 20) Submitted: 9/8/2012 11:59:00 PM
Recs: 0

Upcoming week will be huge runs for NAVB after expected FDA approval, CRTX's positive panel votes, AMRN's NCE status 5 years announcement. Good luck to all.

Member Avatar zzlangerhans (99.82) Submitted: 9/13/2012 2:43:12 PM
Recs: 2

Wow, zero for three. You might be ready to inherit Rodman & Renshaw's title as king of the biopharma contrarian indicators.

Featured Broker Partners


Advertisement